- Home
- RDIB vs IVVD Comparison
RDIB vs IVVD Comparison
Compare RDIB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- IVVD
- Stock Information
- Founded
- RDIB 1937
- IVVD 2020
- Country
- RDIB United States
- IVVD United States
- Employees
- RDIB N/A
- IVVD N/A
- Industry
- RDIB Movies/Entertainment
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- RDIB Consumer Discretionary
- IVVD Health Care
- Exchange
- RDIB Nasdaq
- IVVD Nasdaq
- Market Cap
- RDIB 140.2M
- IVVD 123.8M
- IPO Year
- RDIB N/A
- IVVD 2021
- Fundamental
- Price
- RDIB $10.00
- IVVD $0.66
- Analyst Decision
- RDIB
- IVVD Strong Buy
- Analyst Count
- RDIB 0
- IVVD 3
- Target Price
- RDIB N/A
- IVVD $7.52
- AVG Volume (30 Days)
- RDIB 3.5K
- IVVD 1.7M
- Earning Date
- RDIB 05-14-2025
- IVVD 05-08-2025
- Dividend Yield
- RDIB N/A
- IVVD N/A
- EPS Growth
- RDIB N/A
- IVVD N/A
- EPS
- RDIB N/A
- IVVD N/A
- Revenue
- RDIB $210,527,000.00
- IVVD $25,384,000.00
- Revenue This Year
- RDIB $11.97
- IVVD $606.63
- Revenue Next Year
- RDIB $6.40
- IVVD $83.30
- P/E Ratio
- RDIB N/A
- IVVD N/A
- Revenue Growth
- RDIB N/A
- IVVD N/A
- 52 Week Low
- RDIB $5.78
- IVVD $0.36
- 52 Week High
- RDIB $21.34
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- RDIB 69.57
- IVVD 49.09
- Support Level
- RDIB $9.01
- IVVD $0.46
- Resistance Level
- RDIB $10.00
- IVVD $0.56
- Average True Range (ATR)
- RDIB 0.72
- IVVD 0.07
- MACD
- RDIB 0.28
- IVVD 0.03
- Stochastic Oscillator
- RDIB 100.00
- IVVD 87.21
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.